Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Management and Research|December 29, 2010
Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patternsKeith Shults, Leanne Flye, Lisa Green, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 29, 2006
Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptorsJohn W Ryder, Julie F Falcone, Jason R Manro, et al.
Bioanalysis|January 22, 2013
Preclinical bridging studies: understanding dried blood spot and plasma exposure profilesEnaksha R Wickremsinhe, Naijia H Huang, Basira G Abdul, et al.
Plos One|April 28, 2015
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3Jennifer M Atkinson, Kenneth B Rank, Yi Zeng, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 25, 2003
Developmental expression of human hepatic CYP2C9 and CYP2C19Sevasti B Koukouritaki, Jason R Manro, Sandra A Marsh, et al.
Journal of Pharmaceutical Sciences|February 21, 2012
How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding?Maciej J Zamek-Gliszczynski, Karen E Sprague, Alfonso Espada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 7, 2013
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluoresceinJ William Higgins, Jing Q Bao, Alice B Ke, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 17, 2003
Developmental expression of the major human hepatic CYP3A enzymesJeffrey C Stevens, Ronald N Hines, Chungang Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2013
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including METWenjuan Wu, Chen Bi, Kelly M Credille, et al.
Investigational New Drugs|December 1, 2017
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skippingS Betty Yan, Suzane L Um, Victoria L Peek, et al.
Pageof 2